Non-Hodgkin lymphoma mortality statistics

Coronavirus (COVID-19)

We know that this is an especially worrying time so we have created a key messages document for Health Professionals focussed on safety netting patients presenting with symptoms during the coronavirus outbreak. We have also created a page on the subject specifically for patients on our about cancer hub. We will update that information as guidance changes.

Safety netting patients during covid-19

Deaths

Deaths from non-Hodgkin lymphoma, 2017, UK

 

Proportion of all deaths

Percentage non-Hodgkin lymphoma contributes to total cancer deaths, 2015-2017, UK

Age

Peak rate of non-Hodgkin lymphoma deaths, 2015-2017, UK

 

Trend over time

Change in non-hodgkin lymphoma mortality rates since the early 1970s, UK

Non-Hodgkin lymphoma is the 11th most common cause of cancer death in the UK, accounting for 3% of all cancer deaths (2017).[1-3]

In females in the UK, non-Hodgkin lymphoma is the 10th most common cause of cancer death (3% of all female cancer deaths). In males in the UK it is the 14th most common cause of cancer death (3% of all male cancer deaths).

46% of non-Hodgkin lymphoma deaths in the UK are in females, and 54% are in males.

Non-Hodgkin lymphoma mortality rates (European age-standardised (AS) rates) Open a glossary item are similar to the UK average in all the UK constituent countries.

Non-Hodgkin Lymphoma (C82-C86), Number of Deaths, Crude and European Age-Standardised (AS) Mortality Rates per 100,000 Population, UK, 2017

  England Scotland Wales Northern Ireland UK
Female Deaths 1,866 205 102 61 2,234
Crude Rate 6.6 7.4 6.4 6.4 6.7
AS Rate 6.4 7.0 5.7 6.8 6.4
AS Rate - 95% LCL 6.1 6.0 4.6 5.1 6.2
AS Rate - 95% UCL 6.7 7.9 6.9 8.4 6.7
Male Deaths 2,258 211 139 64 2,672
Crude Rate 8.2 8.0 9.0 7.0 8.2
AS Rate 9.8 9.5 9.7 9.2 9.8
AS Rate - 95% LCL 9.4 8.2 8.1 7.0 9.4
AS Rate - 95% UCL 10.2 10.8 11.3 11.5 10.1
Persons Deaths 4,124 416 241 125 4,906
Crude Rate 7.4 7.7 7.7 6.7 7.4
AS Rate 7.9 8.1 7.5 8.0 7.9
AS Rate - 95% LCL 7.7 7.3 6.5 6.6 7.7
AS Rate - 95% UCL 8.2 8.9 8.4 9.3 8.1

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item around the AS Rate Open a glossary item

References

  1. Data were provided by the Office for National Statistics on request, November 2018. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths.
  2. Data were provided by ISD Scotland on request, October 2018. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp.
  3. Data were provided by the Northern Ireland Cancer Registry on request, March 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2017, ICD-10 C82-C86.

The term non-Hodgkin lymphoma describes a large group of lymphoma subtypes, which differ substantially in their cellular origin and clinical behaviour. The subtypes can be broadly divided into B-cell lymphomas, T-cell lymphomas, and lymphoproliferative disorders not otherwise specified. B-cell lymphomas can be further divided into five main types: diffuse large B-cell lymphoma, marginal zone lymphomas, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma. It is important to recognise the variation between these subtypes when interpreting statistics on NHL as a whole. The Haematological Malignancy Research Network provides detailed incidence statistics for NHL subtypes.

Last reviewed:

Non-Hodgkin lymphoma mortality is strongly related to age, with the highest mortality rates being in older people. In the UK in 2015-2017, on average each year almost 6 in 10 (58%) deaths were in people aged 75 and over.[1-3] This largely reflects higher incidence and lower survival for non-Hodgkin lymphoma in older people.

Age-specific mortality rates rise steadily from around age 45-49 and more steeply from around age 55-59. The highest rates are in the 85 to 89 age group for females and males. Mortality rates are significantly lower in females than males in a number of (mainly older) age groups. The gap is widest at age 40 to 44,when the age-specific mortality rate is 2.2 times lower in females than in males.

Non-Hodgkin Lymphoma (C82-C86), Average Number of Deaths per Year and Age-Specific Mortality Rates per 100,000 Population, UK2015-2017

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item around the AS Rate Open a glossary item

References

  1. Data were provided by the Office for National Statistics on request, November 2018. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths.
  2. Data were provided by ISD Scotland on request, October 2018. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp.
  3. Data were provided by the Northern Ireland Cancer Registry on request, March 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2015-2017, ICD-10 C82-C86.

The term non-Hodgkin lymphoma describes a large group of lymphoma subtypes, which differ substantially in their cellular origin and clinical behaviour. The subtypes can be broadly divided into B-cell lymphomas, T-cell lymphomas, and lymphoproliferative disorders not otherwise specified. B-cell lymphomas can be further divided into five main types: diffuse large B-cell lymphoma, marginal zone lymphomas, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma. It is important to recognise the heterogeneity of these subtypes when interpreting statistics on NHL as a whole. The Haematological Malignancy Research Network provides detailed incidence statistics for NHL subtypes.

Last reviewed:

Non-Hodgkin lymphoma European age-standardised (AS) Open a glossary item mortality rates for females and males combined increased by 80% in the UK between 1971-1973 and 2015-2017.[1-3] The increase was of a similar size in females and males.

For females, non-Hodgkin lymphoma AS mortality rates in the UK increased by 73% between 1971-1973 and 2015-2017. For males, non-Hodgkin lymphoma AS mortality rates in the UK increased by 84% between 1971-1973 and 2015-2017.

Over the last decade in the UK (between 2005-2007 and 2015-2017), non-Hodgkin lymphoma AS mortality rates for females and males combined decreased by 7%. In females AS mortality rates decreased by 9%, and in males rates decreased by 6%.

Non-Hodgkin Lymphoma (C82-C86), European Age-Standardised Mortality Rates per 100,000 Population, UK, 1971-2017

For most cancer types, mortality trends largely reflect incidence and survival trends. For example, rising mortality may reflect rising incidence and stable survival, while falling mortality may reflect rising incidence and rising survival.

Non-Hodgkin lymphoma mortality rates have varied between age groups in females and males combined in the UK since the early 1970s.[1-3] Rates in 0-24s have decreased by 77%, in 25-49s have decreased by 47%, in 50-59s have decreased by 25%, in 60-69s have increased by 21%, in 70-79s have increased by 124%, and in 80+s have increased by 320%.

Non-Hodgkin Lymphoma (C82-C86), European Age-Standardised Mortality Rates per 100,000 Population, By Age, UK, 1971-2017

References

  1. Data were provided by the Office for National Statistics on request, October 2017. Similar data can be found here: http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths.
  2. Data were provided by ISD Scotland on request, October 2017. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp.
  3. Data were provided by the Northern Ireland Cancer Registry on request, December 2017. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 1971-2017, C82-C86.

The term non-Hodgkin lymphoma describes a large group of lymphoma subtypes, which differ substantially in their cellular origin and clinical behaviour. The subtypes can be broadly divided into B-cell lymphomas, T-cell lymphomas, and lymphoproliferative disorders not otherwise specified. B-cell lymphomas can be further divided into five main types: diffuse large B-cell lymphoma, marginal zone lymphomas, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma. It is important to recognise the variation between these subtypes when interpreting statistics on NHL as a whole. The Haematological Malignancy Research Network provides detailed incidence statistics for NHL subtypes.

Last reviewed:

Non-Hodgkin lymphoma (NHL) mortality rates are projected to fall by 20% in the UK between 2014 and 2035, to 8 deaths per 100,000 people by 2035.[1] This includes a larger decrease for males than for females.

For males, non-Hodgkin lymphoma European age-standardised (AS) Open a glossary item mortality rates in the UK are projected to fall by 22% between 2014 and 2035, to 9 deaths per 100,000 by 2035.[1] For females, rates are projected to fall by 20% between 2014 and 2035, to 6 deaths per 100,000 by 2035.[1]

Non-Hodgkin lymphoma (C82-C85), Observed and Projected Age-Standardised Mortality Rates, by Sex, UK, 1979-2035

 

It is projected that 6,129 deaths from non-Hodgkin lymphoma (3,435 in males, 2,694 in females) will occur in the UK in 2035.

References

  1. Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer Incidence and Mortality Projections in the UK Until 2035. Brit J Cancer 2016.

About this data

Data is for: UK, 1979-2014 (observed), 2015-2035 (projected), ICD-10 C82-C85

Projections are based on observed incidence and mortality rates and therefore implicitly include changes in cancer risk factors, diagnosis and treatment. It is not possible to assess the statistical significance of changes between 2014 (observed) and 2035 (projected) figures. Confidence intervals are not calculated for the projected figures. Projections are by their nature uncertain because unexpected events in future could change the trend. It is not sensible to calculate a boundary of uncertainty around these already uncertain point estimates. Changes are described as 'increase' or 'decrease' if there is any difference between the point estimates.

More on projections methodology

Last reviewed:

There is evidence for an association between non-Hodgkin lymphoma mortality and deprivation for females in England, but there is no evidence for an association for males.[1] England-wide data for 2007-2011 show European age-standardised Open a glossary item mortality rates are 24% higher for females living in the most deprived areas compared with the least deprived, but for males the rates are similar for those living in the least and most deprived areas.[1]

Non-Hodgkin Lymphoma (C82-C85), European Age-Standardised Mortality Rates by Deprivation Quintile, England, 2007-2011

The estimated deprivation gradient in non-Hodgkin lymphoma mortality for males and females living in the most and least deprived areas in England has not changed in the period 2002-2011.[1] It has been estimated that there would have been around 130 fewer cancer deaths each year in England during 2007-2011 if all people experienced the same mortality rates as the least deprived.[1]

References

  1. Cancer Research UK and National Cancer Intelligence Network. Cancer by deprivation in England: Incidence, 1996-2010, Mortality, 1997-2011. London: NCIN; 2014.

About this data

Data is for: UK, 2007-2011, ICD-10 C82-C85

Deprivation gradient statistics were calculated using mortality data for 2007-2011. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.